141 related articles for article (PubMed ID: 36072559)
1. Role of lupeol in chemosensitizing therapy-resistant prostate cancer cells by targeting MYC, β-catenin and c-FLIP: in silico and in vitro studies.
Maurya SK; Fatma H; Maurya AK; Mishra N; Siddique HR
In Silico Pharmacol; 2022; 10(1):16. PubMed ID: 36072559
[TBL] [Abstract][Full Text] [Related]
2. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol.
Khan MA; Singh D; Fatma H; Akhtar K; Arjmand F; Maurya S; Siddique HR
Drug Chem Toxicol; 2023 Mar; 46(2):380-391. PubMed ID: 35188013
[TBL] [Abstract][Full Text] [Related]
4. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.
Saleem M; Murtaza I; Tarapore RS; Suh Y; Adhami VM; Johnson JJ; Siddiqui IA; Khan N; Asim M; Hafeez BB; Shekhani MT; Li B; Mukhtar H
Carcinogenesis; 2009 May; 30(5):808-17. PubMed ID: 19233958
[TBL] [Abstract][Full Text] [Related]
5. Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells.
Saleem M; Murtaza I; Witkowsky O; Kohl AM; Maddodi N
Biochem Biophys Res Commun; 2009 Oct; 388(3):576-82. PubMed ID: 19683515
[TBL] [Abstract][Full Text] [Related]
6. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of Therapy Resistant Tumors: Targeting Multiple Cell Signaling Pathways by Lupeol, A Pentacyclic Triterpene.
Maurya SK; Shadab GGHA; Siddique HR
Curr Pharm Des; 2020; 26(4):455-465. PubMed ID: 31969092
[TBL] [Abstract][Full Text] [Related]
9. Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
Wang BJ; Huang SH; Kao CL; Muller CJF; Wang YP; Chang KH; Wen HC; Yeh CC; Shih LJ; Kao YH; Huang SP; Li CY; Chuu CP
PLoS One; 2022; 17(7):e0270803. PubMed ID: 35776912
[TBL] [Abstract][Full Text] [Related]
10. Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol.
Tarapore RS; Siddiqui IA; Saleem M; Adhami VM; Spiegelman VS; Mukhtar H
Carcinogenesis; 2010 Oct; 31(10):1844-53. PubMed ID: 20732907
[TBL] [Abstract][Full Text] [Related]
11. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
12. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
13. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
15. The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/β-catenin signaling.
Tarapore RS; Siddiqui IA; Adhami VM; Spiegelman VS; Mukhtar H
Mol Nutr Food Res; 2013 Nov; 57(11):1950-8. PubMed ID: 23836602
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
17. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.
Murtaza I; Saleem M; Adhami VM; Hafeez BB; Mukhtar H
Cancer Res; 2009 Feb; 69(3):1156-65. PubMed ID: 19176377
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
19. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
20. The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells.
Hellsten R; Stiehm A; Palominos M; Persson M; Bjartell A
Transl Oncol; 2022 Oct; 24():101495. PubMed ID: 35917644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
